PRFX Profile
PainReform Ltd., headquartered in Tel Aviv, Israel, is a clinical-stage specialty pharmaceutical company dedicated to advancing therapeutic solutions for prolonged post-surgical pain relief. Established in 2007, the company focuses on developing innovative treatments, notably PRF-110, a viscous clear oil-based solution designed for direct instillation into surgical wounds. This approach aims to localize and extend analgesic effects, enhancing recovery outcomes for patients undergoing various surgical procedures.
At present, PainReform Ltd. is actively progressing with two Phase 3 clinical trials evaluating the efficacy and safety of PRF-110. These trials specifically target patients undergoing bunionectomy surgery and hernia repair, aiming to validate the therapeutic benefits and commercial viability of the product. The company's research and development efforts are underpinned by rigorous scientific methodologies and regulatory compliance, ensuring robust clinical data and adherence to industry standards.
Beyond its core product development initiatives, PainReform Ltd. remains committed to expanding its pipeline of innovative therapies addressing unmet medical needs in pain management. The company leverages strategic partnerships and collaborations with healthcare professionals and institutions to advance scientific understanding and therapeutic innovation. This collaborative approach reinforces PainReform Ltd.'s position as a leader in the field of post-surgical pain relief.
With a strategic focus on enhancing patient outcomes and advancing healthcare innovation, PainReform Ltd. continues to drive forward with its mission to deliver effective and sustainable solutions for pain management. By combining scientific excellence with a patient-centered approach, the company aims to redefine standards of care and improve quality of life for surgical patients worldwide.
|
